COX-2 inhibitors: increased risk of CV events?

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2001年 / 867卷 / 1期
关键词：
Celecoxib; Naproxen; Rofecoxib; Nabumetone; Adverse Event Reporting System;
D O I：
10.2165/00128415-200108670-00001
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [21] Increased COX-2 selectivity of NSAIDs appears to be associated with increased cardiovascular (CV) risks
    Reactions Weekly, 2006, 1119 (1) : 5 - 5
  • [22] COX-2 inhibitors
    Brooks, PM
    Day, RO
    MEDICAL JOURNAL OF AUSTRALIA, 2000, 173 (08) : 433 - 436
  • [23] COX-2 inhibitors
    Seidenberg, BC
    LANCET, 1999, 353 (9168): : 1978 - 1978
  • [24] COX-2 inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (03) : 122 - 123
  • [25] COX-2 inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1997, 2 (09) : 393 - 393
  • [26] COX-2 inhibitors
    Becker, RC
    TEXAS HEART INSTITUTE JOURNAL, 2005, 32 (03): : 380 - 383
  • [27] COX-2 inhibitors
    Hawkey, CJ
    LANCET, 1999, 353 (9149): : 307 - 314
  • [28] COX-2 inhibitors
    Lawrie, MM
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (07) : 367 - 367
  • [29] Disruption of cholesterol transport by celecoxibb and COX-2 silencing: A potential mechanism of increased cardiovascular (CV) risk
    Edelman, Sari D.
    Anwar, Kamran
    Chan, Edwin S.
    Wirkowski, Peter
    Morano, Jacqueline
    Carsons, Steven E.
    Reiss, Allison B.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (12): : 4244 - 4244
  • [30] Natriuretic response to increased pressure is preserved with COX-2 inhibitors
    Gross, JM
    Dwyer, JE
    Knox, FG
    HYPERTENSION, 1999, 34 (05) : 1163 - 1167
12345